Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant
Completed · Phase 4
Conditions studied: Complications; Contraceptive, Female Lactation
In brief
A highly effective single rod contraceptive implant is now available for use in the US. Delays in the insertion of the device until later in the postpartum period may negatively impact initiation rates. The objective of this study is to compare outcomes of early postpartum insertion (prior to postpartum hospital discharge) of the etonogestrel-releasing contraceptive implant with routine postpartum insertion at 4-8 weeks after delivery. Primary outcome of interest will be time to lactogenesis. Secondary outcomes will include rates of breastfeeding supplementation, infant growth, vaginal bleeding patterns, incidence of side effects, time to resume sexual intercourse after delivery, and incidence of missed routine postpartum follow-up. In addition, a subset of patients who randomize to early postpartum insertion will have expressed breastmilk ascertained for nutrient composition.
Key facts
- Study ID
- NCT00847587
- Run by
- University of Utah
- People needed
- 69
- Starts
- 2009-01-01
- Expected to finish
- 2010-05-01
- Last updated by the study team
- 2016-04-18
Who can join
Age: 18 and older, up to 40. Sex: female. Healthy volunteers: accepted.
You may not qualify if…
- obstetric complications including anemia with hematocrit<30,
- transfusion,
- infection,
- severe pregnancy induced hypertension,
- prolonged hospitalization,
- coagulopathy,
- liver disease,
- undiagnosed genital bleeding,
- or other relative contraindication to Implanon® insertion (known or suspected pregnancy, known, suspected, or history of breast cancer, or hypersensitivity to any of the components in Implanon®).
- Women taking drugs that are potent inducers of hepatic enzymes will also be excluded, including barbiturates, griseofulvin, rifampin, phenylbutazone, phenytoin, carbamazepine, felbamate, oxcarbazepine, topiramate, modafinil, protease inhibitors, and herbal products including St. John's Wort.
Where it is running
- University of Utah Hospital — Salt Lake City, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.